Ascendis Pharma A/S
ASND · US · Pharma & Biotech · $234 a share (close of 15 Sep 2026)
Available company data, source links and archived checks for Ascendis Pharma A/S. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.
The ownership tape — last 90 days, from disclosures
▲ Bienaime Jean Jacques (Director) bought shares worth $270k · 14 Aug · SEC Form 4
▲ Bienaime Jean Jacques (Director) bought shares worth $222k · 14 Aug · SEC Form 4
Who holds it — from the filings
STATE STREET CORPAMERIPRISE FINANCIAL INCFrazier Life Sciences Management, L.P.NEUBERGER BERMAN GROUP LLCWELLS FARGO & COMPANY/MNregister as filed
2026-08-31
Filing timeline — what the company told the exchange
- 6-K
1
d183438d6k.htm
6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-…
14 Sep 2026 · document
- 6-K
1
d52763d6k.htm
6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-1…
14 Sep 2026 · document
- 6-K
1
d152057d6k.htm
6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-…
09 Sep 2026 · document
Follow this company without reading every document yourself.
Keep its available filings, dated fact checks and disclosure alerts together.
Your saved country sets your market and its research schedule.
Start free — first week on us →
India ₹149/month · Rest of world US$4.99/month after the free trial · research, not investment
advice · cancel any time